ZURICH, Feb 27 (Reuters) - Swiss drug maker Novartis (NOVN.VX: Quote, Profile, Research) has received an “approvable letter” from U.S. drug regulators for its Aclasta drug for use in the treatment of Paget’s disease, a painful bone disorder, the firm said.
